Form 8-K - Current report:
SEC Accession No. 0001193125-25-139899
Filing Date
2025-06-12
Accepted
2025-06-12 16:18:01
Documents
17
Period of Report
2025-06-11
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d908664d8k.htm   iXBRL 8-K 38181
2 EX-4.1 d908664dex41.htm EX-4.1 77314
3 EX-5.1 d908664dex51.htm EX-5.1 16526
4 EX-10.1 d908664dex101.htm EX-10.1 164290
9 GRAPHIC g908664g0612093841057.jpg GRAPHIC 2534
  Complete submission text file 0001193125-25-139899.txt   529536

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA tpst-20250611.xsd EX-101.SCH 3884
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE tpst-20250611_def.xml EX-101.DEF 13699
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE tpst-20250611_lab.xml EX-101.LAB 22683
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tpst-20250611_pre.xml EX-101.PRE 14667
20 EXTRACTED XBRL INSTANCE DOCUMENT d908664d8k_htm.xml XML 5520
Mailing Address 2000 SIERRA POINT PARKWAY SUITE 400 BRISBANE CA 94005
Business Address 2000 SIERRA POINT PARKWAY SUITE 400 BRISBANE CA 94005 415-798-8589
Tempest Therapeutics, Inc. (Filer) CIK: 0001544227 (see all company filings)

EIN.: 451472564 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35890 | Film No.: 251042728
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)